インドのHPV (ヒトパピローマウイルス) ワクチン市場の評価：タイプ・適応症・合成法・流通チャネル・地域別の機会および予測 (2017-2031年)

インドのHPV (ヒトパピローマウイルス) ワクチンの市場規模は、2023年の13億米ドルから、2024年から2031年の予測期間中は11%のCAGRで推移し、2031年には30億米ドルの規模に成長すると予測されています。

市場規模の拡大には、子宮頸癌やHPVに関連するその他の疾患の有病率の増加によるHPVワクチン接種の重要性に対する意識の高まりなど、いくつかの要因が寄与しています。さらに、政府主導のさまざまなイニシアチブやワクチン接種プログラム、ワクチン開発技術の進歩が、ワクチン接種に対する意識の向上に重要な役割を果たしています。

近年、インドのHPVワクチン市場は、HPV感染とその関連疾患を予防することの重要性が認識されるようになったことを背景に、大きな成長を遂げています。子宮頸癌は、インドで数百万人の女性を悩ませている主要な原因であり、主に一般的な性感染症であるHPVと関連しています。HPVワクチン接種の利点と子宮頸癌の負担軽減の可能性についての認識の高まりにより、インドではHPVワクチンの需要が急増しています。これを受けて、インド政府や様々なヘルスケア機関は、特に若い女性や女児に焦点を当て、ワクチンの普及を促進するため、数多くのイニシアチブやワクチン接種プログラムを実施しています。

さらに、ワクチン開発技術の進歩により、インドのHPV市場では、より効果的で利用しやすいワクチンの導入が整備されています。こうした画期的な進歩により、HPVワクチン接種の有効性と安全性に関して、ヘルスケアプロバイダーや個人の間に信頼が浸透しています。インドにおけるHPVワクチンの人気の高まりは、HPV感染と闘い、全国の女性の幸福を守る努力における有望な前進のシグナルであり、インドのHPVワクチン市場にプラスの影響を与えています。

2023年12月、Family Planning Association of India (FPAI) は、子宮頸癌から女児と女性を守るため、全国的なHPVワクチン接種キャンペーンを開始しました。このキャンペーンの目的は、全国に広がるFPAIの40の支部を通じて、2万人以上の女性と女児にワクチンを接種することです。

当レポートでは、インドのHPV (ヒトパピローマウイルス) ワクチンの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 インドのHPV (ヒトパピローマウイルス) ワクチン市場の展望

• 市場規模・予測
• タイプ別
  • 二価
  • 四価
  • 九価
• 適応症別
  • 子宮頸癌
  • 肛門癌
  • 外陰部・膣癌
  • 陰茎癌
  • 口腔咽頭癌
  • その他
• 合成法別
  • 核酸ベース
  • ペプチドベース
  • タンパク質ベース
  • 細胞ベース
  • 生ベクターワクチン
• 流通チャネル別
  • 病院
  • 小売薬局
  • オンライン薬局
  • NGO
• 地域別
  • 北部
  • 南部
  • 東部
  • 西部・中央部
• 企業別市場シェア

第5章 市場マッピング

• タイプ別
• 疾患別
• 合成法別
• 流通チャネル別
• 地域別

第6章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第7章 市場力学

• 成長促進因子
• 成長阻害因子 (課題・制約)

第8章 規制枠組みとイノベーション

• 臨床試験
• 特許情勢
• 規制当局の承認
• イノベーション/新興技術

第9章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)
• 特許分析 (該当する場合)

第10章 価格分析

第11章 ケーススタディ

第12章 主要企業の展望

• GlaxoSmithKline Plc.
• Merck & Co., Inc.
• Beijing Health Guard Biotechnology, Inc.
• China National Biotec Group Company Limited
• Shanghai Bovax Biotechnology Co., Ltd.
• Walvax Biotechnology Co., Ltd
• Xiamen Innovax Biotech Co., Ltd.
• Serum Institute of India Pvt. Ltd.
• Eyegene Inc.
• Janssen Biotech, Inc.

第13章 戦略的提言

第14章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India Human Papillomavirus Vaccine Market, By Value, in USD Billion, FY2017-FY2031F
• Figure 2. India Human Papillomavirus Vaccine Market, By Volume, in Thousand Units, FY2017-FY2031F
• Figure 3. India Human Papillomavirus Vaccine Market Share (%), By Type, FY2017-FY2031F
• Figure 4. India Human Papillomavirus Vaccine Market Share (%), By Disease Indication, FY2017-FY2031F
• Figure 5. India Human Papillomavirus Vaccine Market Share (%), By Method of Synthesis, FY2017-FY2031F
• Figure 6. India Human Papillomavirus Vaccine Market Share (%), By Distribution Channel, FY2017-FY2031F
• Figure 7. India Human Papillomavirus Vaccine Market Share (%), By Region, FY2017-FY2031F
• Figure 8. By Type Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 9. By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 10. By Method of Synthesis Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 11. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), FY2023
• Figure 12. By Region Map-Market Size (USD Billion) & Growth Rate (%), FY2023

India human papillomavirus vaccine market is projected to witness a CAGR of 11% during the forecast period FY2024-FY2031, growing from USD 1.3 billion in FY2023 to USD 3 billion in FY2031. Several factors are contributing to the growing market size, including a rise in awareness about the importance of HPV vaccination due to the increasing prevalence of cervical cancer and other diseases associated with HPV. In addition, various government-led initiatives and vaccination programs, as well as advancements in vaccine development technology, have played a crucial role in increasing awareness about vaccination.

In recent years, India human papillomavirus vaccine market has experienced substantial growth, driven by an increasing recognition of the significance of preventing HPV infections and their associated diseases. Cervical cancer, a leading cause of concern for millions of women in India, is primarily linked to HPV, a common sexually transmitted infection. The increasing awareness about the benefits of HPV vaccination and its potential to reduce the burden of cervical cancer has resulted in a surge in demand for HPV vaccines in India. In response, the Indian government and various healthcare organizations have undertaken numerous initiatives and vaccination programs to promote widespread vaccine adoption, with a particular focus on young girls and women.

Furthermore, advancements in vaccine development technology have paved the way for the introduction of more effective and accessible vaccines in India human papillomavirus vaccine market. These breakthroughs have instilled confidence among healthcare providers and individuals regarding the efficacy and safety of HPV vaccination. The rising popularity of HPV vaccines in India signals a promising step forward in the effort to combat HPV infections and safeguard the well-being of women across the country, positively impacting the India human papillomavirus vaccine market.

In December 2023, the Family Planning Association of India (FPAI) initiated a nationwide HPV vaccination drive for girls and women to protect them against cervical cancer. The campaign's objective is to vaccinate over 20,000 women and girls through the FPAI's 40 branches spread across the country.

Increasing Awareness About HPV Immunization

Increasing awareness about the importance of HPV vaccination has led to significant growth of India human papillomavirus vaccine market. While efforts implemented by governments and healthcare organizations have increased screening for cervical cancer, the primary prevention achieved through HPV immunization has played a crucial role in diminishing the cervical cancer burden in India. The effectiveness of these strategies has been evident not only in high-income countries (HICs) but has also resulted in higher rates of adoption of the HPV vaccine and widespread approval in low- and lower-middle-income countries (LLMICs). International collaborations between WHO, United Nations Population Fund, UN Women, and the IPVS (Indian Post Visibility System), along with healthcare providers who are trusted sources of health advice, persist in their efforts to inform and promote HPV immunization. In the context of school-based vaccination programs, educators, school administrators, and the Ministry of Education also play a crucial role in conveying the advantages of HPV vaccination.

Increasing Incidence of HPV-related diseases

According to the National Cancer Registry Programme of the Indian Council of Medical Research, the estimated number of cervical cancer cases in India was over 340,000 in 2023. The incidence will further increase in the coming years because of factors such as smoking and excessive alcohol consumption, urbanization and changing lifestyles, delayed childbearing and multiple sexual partners, limited access to quality healthcare and diagnostic facilities in certain regions of India, and cultural taboos and stigmatization of certain cancers and sexually transmitted infections. This way, increasing incidences of HPV-related diseases will continue to have a positive effect on India human papillomavirus vaccine market.

Government Initiatives

Government initiatives has greatly influenced the India human papillomavirus vaccine market. The Indian government has taken proactive and comprehensive measures to tackle the public health challenge posed by human papillomavirus (HPV) infections. The primary goal of these initiatives is to increase awareness about the advantages of HPV vaccination and ensure broad vaccine coverage, with a specific focus on young girls and women. In addition to conducting awareness campaigns, the government has initiated vaccination programs and several educational initiatives to distribute information about HPV, its risks, and preventive measures.

In December 2022, the National Technical Advisory Group for Immunization (NTAGI) recommended the inclusion of the HPV vaccine in the Universal Immunization Programme (UIP). The plan involved a one-time catch-up vaccination for 9-14-year-old adolescent girls, followed by routine introduction at 9 years of age. To facilitate this vaccination drive, schools played a significant role in the implementation, adopting a grade-based approach for girls in 5th to 10th grades.

Quadrivalent Vaccines are Witnessing Rapid Growth in Demand

Increasing demand for quadrivalent vaccines has caused growth in India human papillomavirus vaccine market. The quadrivalent HPV vaccine consists of a combination of four HPV type-specific Virus-Like Particles (VLPs) derived from HPV 6, 11, 16, and 18 L1 proteins, along with an aluminum adjuvant. Clinical trials have demonstrated the vaccine's remarkable efficacy in preventing persistent HPV infection, cervical cancer precursor lesions, vaginal and vulvar cancer precursor lesions, and genital warts caused by HPV types 6, 11, 16, or 18 in females who have not been previously infected with the respective HPV type. It is essential to note that the vaccine does not offer protection against diseases caused by HPV types that females may already be infected with at the time of vaccination. Gardasil, a quadrivalent vaccine developed by Merck & Co. in October 2022, revealed the initial results of the clinical trial to test for two versus three doses of Gardasil vaccine in India. The clinical trials were carried out by All India Institute of Medical Sciences, New Delhi, in collaboration with several other institutes and hospitals.

High Prevalence and Government Initiatives for HPV in Eastern Region

In the Eastern region, cervical cancer is growing at a rapid rate. The district of Papumpare in the Indian state of Arunachal Pradesh has the highest incidence rate of cervical cancer (AAR-27.7) in Asia, according to the National Cancer Registry Programme. Mizoram's Aizawl district came next, with an incidence of AAR-27.3, followed by Arunachal Pradesh's Pasighat district, with an incidence of AAR-20.3. To reduce the prevalence of HPV, the central and state governments have started various initiatives aimed towards increasing awareness about HPV and increasing immunization drives. For example, Sikkim state made a landmark decision to be the first state in India to introduce HPV vaccine statewide. In June 2023, the Union Health Ministry administered the human papillomavirus (HPV) vaccine in the Mizoram state as a part of the universal immunization program.

Future Market Scenario (2024 - 2031F)

Increased awareness and education campaigns regarding the link between HPV and cervical cancer in India are expected to boost the adoption rate of the vaccine in the India human papillomavirus vaccine market.

The India human papillomavirus vaccine market may be greatly impacted by the government's efforts to promote HPV vaccination, whether by including it in national immunization programs or by providing financial assistance.

Future advancements in vaccination science may lead to the development of HPV vaccinations that offer protection against new virus strains. As a result, the India human papillomavirus vaccine market may become more effective, increasing their public appeal, and maybe expanding the age range of individuals who can receive vaccinations.

Collaboration between vaccine producers, authorities, non-governmental organizations, and healthcare professionals in the India human papillomavirus vaccine market may expand the availability of HPV vaccines throughout the country, particularly in rural and impoverished areas.

Key Players Landscape and Outlook

India human papillomavirus vaccine market is undergoing a notable transformation, marked by a rising trend of mergers and collaborations among pharmaceutical firms and research institutions. These strategic partnerships are emerging as pivotal catalysts propelling the progress of HPV vaccine development, production, and distribution in India. Considering the increasing demand for HPV vaccines and the mounting recognition of their significance in cervical cancer and HPV-linked ailments, notable players within India's pharmaceutical sector are embracing the potency of collaboration.

For instance, in January 2023, India celebrated a significant milestone with the launch of its first domestically developed Quadrivalent Human Papillomavirus vaccine (qHPV) named 'CERVAVAC.' This achievement was made possible through a collaborative effort between the Serum Institute of India (SII), the Department of Biotechnology (DBT), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation. 'CERVAVAC' promises to play a crucial role in preventing HPV infections and associated diseases.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. India Human Papillomavirus Vaccine Market Outlook, FY2017-FY2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Type
  • 4.2.1. Bivalent
  • 4.2.2. Quadrivalent
  • 4.2.3. Nonavalent
• 4.3. By Disease indication
  • 4.3.1. Cervical cancer
  • 4.3.2. Anal cancer
  • 4.3.3. Vulvar & Vaginal cancer
  • 4.3.4. Penile cancer
  • 4.3.5. Oropharyngeal cancer
  • 4.3.6. Others
• 4.4. By Method of Synthesis
  • 4.4.1. Nucleic acid-based
    • 4.4.1.1. DNA
    • 4.4.1.2. mRNA
  • 4.4.2. Peptide-based
  • 4.4.3. Protein-based
  • 4.4.4. Cell-based
  • 4.4.5. Live vector vaccine
• 4.5. By Distribution Channel
  • 4.5.1. Hospital
  • 4.5.2. Retail Pharmacy
  • 4.5.3. Online Pharmacy
  • 4.5.4. Non-Governmental Organizations
• 4.6. By Region
  • 4.6.1. North
  • 4.6.2. South
  • 4.6.3. East
  • 4.6.4. West and Central
• 4.7. By Company Market Share (%), FY2023

5. Market Mapping, FY2023

• 5.1. By Type
• 5.2. By Disease Indication
• 5.3. By Method of Synthesis
• 5.4. By Distribution Channel
• 5.5. By Region

6. Macro Environment and Industry Structure

• 6.1. Supply Demand Analysis
• 6.2. Import Export Analysis
• 6.3. Value Chain Analysis
• 6.4. PESTEL Analysis
  • 6.4.1. Political Factors
  • 6.4.2. Economic System
  • 6.4.3. Social Implications
  • 6.4.4. Technological Advancements
  • 6.4.5. Environmental Impacts
  • 6.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 6.5. Porter's Five Forces Analysis
  • 6.5.1. Supplier Power
  • 6.5.2. Buyer Power
  • 6.5.3. Substitution Threat
  • 6.5.4. Threat from New Entrant
  • 6.5.5. Competitive Rivalry

7. Market Dynamics

• 7.1. Growth Drivers
• 7.2. Growth Inhibitors (Challenges and Restraints)

8. Regulatory Framework and Innovation

• 8.1. Clinical Trials
• 8.2. Patent Landscape
• 8.3. Regulatory Approvals
• 8.4. Innovations/Emerging Technologies

9. Key Players Landscape

• 9.1. Competition Matrix of Top Five Market Leaders
• 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, FY2023)
• 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 9.4. SWOT Analysis (For Five Market Players)
• 9.5. Patent Analysis (If Appliable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

• 12.1. GlaxoSmithKline Plc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Merck & Co., Inc.
• 12.3. Beijing Health Guard Biotechnology, Inc.
• 12.4. China National Biotec Group Company Limited
• 12.5. Shanghai Bovax Biotechnology Co., Ltd.
• 12.6. Walvax Biotechnology Co., Ltd
• 12.7. Xiamen Innovax Biotech Co., Ltd.
• 12.8. Serum Institute of India Pvt. Ltd.
• 12.9. Eyegene Inc.
• 12.10. Janssen Biotech, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us & Disclaimer